Anixa Biosciences (ANIX)
NASDAQ:ANIX
Want to see ANIX full AI Analyst Report?
ANIX Stock Chart & Stats
$3.16
-$0.08(-3.60%)
At close: 4:00 PM EST
$3.16
-$0.08(-3.60%)
Day’s Range― - ―
52-Week Range$2.44 - $5.46
Previous CloseN/A
Volume56.82K
Average Volume (3M)204.54K
Market Cap
$99.58M
Enterprise Value$99.56M
Total Cash (Recent Filing)$14.20M
Total Debt (Recent Filing)$193.00K
Price to Earnings (P/E)―
Beta0.69
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding33,527,860
10 Day Avg. Volume193,788
30 Day Avg. Volume204,545
Financial Highlights & Ratios
PEG Ratio0.96
Price to Book (P/B)8.84
Price to Sales (P/S)0.00
P/FCF Ratio-18.69
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.24K
Enterprise Value/Ebitda-9.03
Forecast
1Y Price Target
$10.50Price Target Upside232.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Early CAR-T Efficacy And Dose Escalation PotentialLow-dose lira-cel treatment in ovarian cancer patients produced survival outcomes that exceeded expectations for the cohort and demonstrated a clean safety profile, enabling planned dose escalation and evaluation of strategies to boost efficacy.
Early Clinical Safety And Immune ResponsePhase 1 results showed the vaccine was well tolerated and induced protocol-defined immune responses in the majority of participants, supporting advancement to further testing.
Manufacturing PartnershipA development and manufacturing agreement with Cytovance secures clinical-grade vaccine supply for upcoming trials, reducing execution risk for clinical development.
Bears Say
Limited Evidence From Small Safety StudyThe ovarian study is primarily designed to assess safety and the extended survival observations come from a small, anecdotal patient set, limiting the strength of efficacy conclusions.
Valuation RiskAnalyst valuation models apply substantial discounts for clinical trial and development risk, which depress near-term valuation despite recent clinical advances.
Anixa Biosciences News
ANIX FAQ
What was Anixa Biosciences’s price range in the past 12 months?
Anixa Biosciences lowest stock price was $2.44 and its highest was $5.46 in the past 12 months.
What is Anixa Biosciences’s market cap?
Anixa Biosciences’s market cap is $99.58M.
When is Anixa Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Anixa Biosciences’s earnings last quarter?
Currently, no data Available
Is Anixa Biosciences overvalued?
According to Wall Street analysts Anixa Biosciences’s price is currently Undervalued.
Does Anixa Biosciences pay dividends?
Anixa Biosciences does not currently pay dividends.
What is Anixa Biosciences’s EPS estimate?
Anixa Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anixa Biosciences have?
Anixa Biosciences has 33,527,860 shares outstanding.
What happened to Anixa Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Anixa Biosciences?
Currently, no hedge funds are holding shares in ANIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anixa Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (232.28% Upside)
$10.50 (232.28% Upside)
Blogger Sentiment
Bullish
ANIX Sentiment 70%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $30.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.40%
12-Months-Change
Fundamentals
Return on Equity
-65.55%
Trailing 12-Months
Asset Growth
-19.43%
Trailing 12-Months
Company Description
Anixa Biosciences
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
ANIX Stock 12 Month Forecast
Average Price Target
$10.50
▲(232.28% Upside)
Technical Analysis
Atossa Therapeutics
―
Champions Oncology
―
OKYO Pharma Limited Sponsored ADR
―
Contineum Therapeutics, Inc. Class A
―
Actuate Therapeutics, Inc.
―
Ownership Overview
5.38% Insiders
4.65% Mutual Funds
0.27% Other Institutional Investors
85.65% Public Companies and
Individual Investors